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Abstract
Background: Abnormalities of 11q23 involving the MLL gene are found in approximately 10% of human
leukemias. To date, nearly 100 different chromosome bands have been described in rearrangements involving
11q23 and 64 fusion genes have been cloned and characterized at the molecular level. In this work we present the
identification of a novel MLL fusion partner in a pediatric patient with de novo biphenotypic acute leukemia.
Methods: Cytogenetics, fluorescence in situ hybridization (FISH), molecular studies (RT-PCR and LDI-PCR), and
bioinformatic sequence analysis were used to characterize the CT45A2 gene as novel MLL fusion partner in
pediatric acute leukemia.
Results: Fluorescence in situ hybridization of bone marrow G-banded metaphases demonstrated a cryptic insertion
of 11q23 in Xq26.3 involving the MLL gene. Breakpoint fusion analysis revealed that a DNA fragment of 653 kb
from 11q23, containing MLL exons 1-9 in addition to 16 other 11q23 genes, was inserted into the upstream region
of the CT45A2 gene located at Xq26.3. In addition, a deletion at Xq26.3 encompassing the 3’ region of the DDX26B
gene (exons 9-16) and the entire CT45A1 gene was identified. RNA analysis revealed the presence of a novel MLL-
CT45A2 fusion transcript in which the first 9 exons of the MLL gene were fused in-frame to exon 2 of the CT45A2
gene, resulting in a spliced MLL fusion transcript with an intact open reading frame. The resulting chimeric
transcript predicts a fusion protein where the N-terminus of MLL is fused to the entire open reading frame of
CT45A2. Finally, we demonstrate that all breakpoint regions are rich in long repetitive motifs, namely LINE/L1 and
SINE/Alu sequences, but all breakpoints were exclusively identified outside these repetitive DNA sequences.
Conclusion: We have identified CT45A2 as a novel spliced MLL fusion partner in a pediatric patient with de novo
biphenotypic acute leukemia, as a result of a cryptic insertion of 11q23 in Xq26.3. Since CT45A2 is the first Cancer/
Testis antigen family gene found fused with MLL in acute leukemia, future studies addressing its biologic relevance
for leukemogenesis are warranted.
Background
Abnormalities of 11q23 involving the MLL gene are
found in approximately 10% of human leukemias [1].
MLL rearrangements are present in >70% of infant leu-
kemias, irrespective of the immunophenotype being
more consistent with acute lymphoblastic leukemia
(ALL) or acute myeloid leuk e m i a( A M L ) ,b u ta r el e s s
frequent in leukemias from older children [2]. MLL
translocations are also found in approximately 10% of
adult AML, and can also be found in a proportion of
patients with therapy-related leukemia after treatment
for other malignancies with topoisomerase II inhibitors
[3]. Although clinically and morphologically heteroge-
neous, MLL-rearranged ALL and AML show unique
gene expression profiles [4,5].
To date, nearly 100 different chromosome bands have
been described in rearrangements involving 11q23 and
64 fusion genes have been cloned and characterized at
the molecular level [6]. The most common MLL fusion
partners are AFF1/AF4 (4q21), MLLT3/AF9 (9p23),
MLLT1/ENL (19p13.3), MLLT10/AF10 (10p12), MLLT4/
AF6 (6q27), ELL (19p13.1), EPS15/AF1P (1p32), MLLT6/
AF17 (17q21), and SEPT6 (Xq24) [6]. Usually, MLL
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joining (NHEJ) DNA repair pathway following DNA
damage [7]. Reciprocal chromosomal translocations are
the most frequent events associated with the genetic
recombination of MLL, but other mechanisms have been
identified, including internal partial tandem duplication
(MLL-PTD), chromosome 11 deletions or inversions, and
several types of complex MLL rearrangements [6]. Occa-
sionally, chromosomal translocation or deletion have
been described to originate MLL spliced fusions, which
arise by fusing the 5’ MLL region to downstream located
partner genes [8]. In the present study, we have identified
the CT45A2 gene as a novel fusion partner of MLL in a
pediatric patient with de novo biphenotypic acute leuke-
mia (BAL), as a result of a cryptic insertion of 11q23
material in Xq26 resulting in a spliced MLL fusion.
Methods
Patient Data
A 6-year-old boy was admitted to the Portuguese
Oncology Institute (Porto, Portugal) with a history of
fever, asthenia and cutaneous pallor. Peripheral blood
analysis revealed anemia (Hb 6.3 g/dl) and bicytopenia.
Bone marrow analysis revealed the presence of 51% of
blasts with the immunophenotype CD3+, CD13+,
CD33+, and CD117+, which lead to the diagnosis of
biphenotypic phenotype (T/myeloid) acute leukemia. No
blasts were detected in the cerebrospinal fluid. He was
treated according to the ELAM 02 protocol (aracytine,
mitoxantrone and methotrexate) and entered complete
remission after induction chemotherapy. Seven months
later he was submitted to allogeneic bone marrow trans-
plantation with umbilical cord hematopoietic progeni-
tors, but the patient showed evidence of relapse after
one year. Treatment with the AML relapse protocol was
started, but only partial remission had been achieved
four months later. The patient underwent a haploidenti-
cal transplant with his mother’s peripheral blood cell
progenitors, but the disease relapsed again and the
patient died nine months later.
Chromosome Banding and Molecular Cytogenetics
The diagnostic bone marrow sample was cultured for
24 hours in RPMI 1640 medium with GlutaMAX-I
(Invitrogen, London, UK) supplemented with 20% fetal
bovine serum (Invitrogen, London, UK). Chromosome
preparations were made by standard methods and
banded by trypsin-Leishman. Karyotypes were
described according to the International System for
Human Cytogenetic Nomenclature [9]. Fluorescence in
situ hybridization (FISH) analysis was performed using
the LSI MLL Dual-Color, Break-Apart Probe and LSI
IGH/BCL2 Dual-Color, Dual Fusion Probe (Vysis,
Downers Grove, USA), respectively, in previously
stained metaphases that have been destained and pro-
cessed for FISH as described [10].
RNA and DNA Extraction
High molecular weight DNA and RNA were extracted
from the bone marrow sample using 1 ml of Tripure
isolation reagent (Roche Diagnostics, Indianapolis,
USA), according to the manufacturer’s instructions.
Long-Distance-Inverse Polymerase Chain Reaction
(LDI-PCR)
The DNA sample was treated and analyzed as previously
described [11,12]. Briefly, 1 μg of genomic DNA was
digested with restriction enzymes and self-ligated to
form DNA circles. Amplification was performed with
specific primers for fusion sequences on der(11) and der
(X). LDI-PCR reactions were performed as described
[12] and according to the manufacturer’s recommenda-
tions (PCR Extender System, 5 Prime, Hamburg, Ger-
many). Amplified products were analyzed on a 1%
agarose gel (SeaKem LE Agarose, Rockland, USA). PCR
amplimers were isolated from the gel and subjected to
DNA sequence analyses to obtain the patient-specific
fusion sequences. After sequencing, unknown sequences
were characterized by blasting the human genome data-
base (Genomic BLAST, http://blast.ncbi.nlm.nih.gov/
Blast.cgi).
Reverse-Transcription Polymerase Chain-Reaction (RT-
PCR)
For cDNA synthesis, 1 μgo fR N Aw a ss u b j e c t e dt o
reverse transcription with random hexamers using the
Superscript III First-Strand Synthesis System for RT-
PCR (Invitrogen, Carlsbad, USA), according to the man-
ufacturer’s instructions. RT-PCR assay for detection of
MLL-CT45A2 fusion transcripts was performed with a
forward primer (MLL-S; 5’-GAGGATCCTGCCCCAAA-
GAAAAG-3’) located in MLL exon 8 (GenBank
accession no. NM_005933) and a reverse primer
(CT45A2-AS; 5’- GGCCATCCTCTGCCTTTTC-3’)
located in CT45A2 exon 2 (GenBank accession no.
NM_152582). Additional primers in the MLL breakpoint
cluster region (exons 9 to 13) and CT45A2 open reading
frame (exons 3 to 5) were used to exclude the presence
of additional splice variants (data not shown). PCR reac-
tions were performed in a 50 μl reaction volume con-
taining 2 μl of synthesized cDNA, 5 μl of 10× GeneAmp
PCR buffer II (100 mM Tris-HCl pH 8.3, 500 mM KCl)
(Applied Biosystems, Foster City, USA), 5 μlo f2 5m M
MgCl2,0 . 4μl dNTP mix (25 mM each dNTP) (Applied
Biosystems), 0.4 mM of each primer (Metabion, Mar-
tinsried, Germany), and 1 unit of AmpliTaq Gold DNA
Polymerase (Applied Biosystems). Reaction tubes were
kept on ice at all times to prevent non-specific
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by 35 cycles of 30 sec. at 95°C, 1 min at 63°C, and 1.5
min at 72°C, followed by a final elongation of 10 min at
72°C on a GeneAmp PCR System 9700 (Applied Biosys-
tems). Amplified products were analyzed on a 2% agar-
ose gel (SeaKem LE Agarose) and the results were
visualized in an image analyzer ImageMaster VDS
(Amersham Biosciences, Little Chalfont, UK).
Bioinformatic Sequence Analysis
Search for DNA sequence motifs known to be asso-
ciated with site-specific recombination, mutation, clea-
vage, and gene rearrangement, and repetitive sequence
elements spanning or in the vicinity of deletion and
insertion breakpoints [13,14] was performed with SEQ
tools [15] and RepeatMasker [16]. Search for repetitive
sequence homology was performed with ClustalW [17].
Results
Karyotyping and Molecular Cytogenetics
The bone marrow cytogenetic analysis revealed abnormal-
ities of chromosomes 14 and 17 and monosomy of chro-
mosome 18 (Figure 1A-B). FISH analysis on previously
G-banded metaphases showed a cryptic insertion of the 5’
MLL gene region in Xq22~25 (Figure 1C), which sug-
gested a rearrangement of the MLL gene, and also the pre-
sence of a BCL2 gene copy on the der(17). Based on the
chromosome banding and FISH findings, the karyotype
was described as 45,XY,add(14)(q24),add(17)(p13),-18[8].
ish ins(X;11)(q22~25;q23q23)(MLL5’+;MLL5’-,MLL3’+),
Figure 1 Cytogenetic analysis of the bone marrow sample of the AML patient. (A) Karyogram showing abnormalities of chromosomes 14
and 17 and monosomy of chromosome 18. The same metaphase after G-banding (B) and after destaining and processed for dual-color FISH
analysis (C) showing a cryptic insertion of the 5’ MLL gene region (green) in Xq22~25.
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(BCL2+)/46,XY[12].
Characterization of the 11q23 and Xq22~25 Genomic
Breakpoints
Using LDI-PCR as described above, the patient’ss a m -
ple was screened for germline and non-germline PCR
amplimers that were subjected to sequence analysis.
The results implicated that a large fragment of 653,099
bp from chromosome 11q23 was inserted into Xq26.3
(Figure 2). We determined that the 5’ and 3’ breaks in
11q23 occurred 2,931 bp downstream of the FXYD2
g e n ea n d8 9b pu p s t r e a mo fMLL exon 10, respec-
tively, with 19 bp being deleted from MLL intron 9
(TGTTTTTTAGATCTATTAA) and with the insertion
of two nucleotides at the breakpoint junction (GG; see
Figure 2A). The insertion of 11q23 material into
Xq26.3 contained the 5’ MLL region (exons 1 to 9) in
addition to 16 other 11q23 genes (FXYD6, TMPRSS13,
IL10RA, APOO2962.2, TMPRSS4, SCN4B, SCN2B,
AMICA1, MPZL3, MPZL2, CD3E, CD3D, CD3G,
UBE4A, ATP5L,a n dAP001267.2;s e eF i g u r e2 B ) .
Regarding Xq26.3, we found that the insertion had
occurred in DDX26B intron 8, 550 bp downstream of
DDX26B e x o n8a n d3 , 9 5 1b pu p s t r e a mo ft h e
CT45A2 gene, with the insertion of two (CG) and
three additional nucleotides (GAA) at the breakpoint
junctions, respectively (Figure 2B). In addition to the
Figure 2 Schematic representation of the cryptic insertion of 11q23 sequences in Xq26.3. The 11q23 breaks occurred 2,931 bp
downstream of the FXYD2 gene and 89 bp upstream of MLL exon 10, respectively (A). A large fragment of 653,099 bp from chromosome 11q23
was inserted in Xq26.3 (B), leading to the transfer to Xq26.3 not only of the 5’ MLL region (exons 1 to 9) but also of 16 other genes (FXYD6,
TMPRSS13, IL10RA, APOO2962.2, TMPRSS4, SCN4B, SCN2B, AMICA1, MPZL3, MPZL2, CD3E, CD3D, CD3G, UBE4A, ATP5L, and AP001267.2). The insertion
resulted in the disruption of the DDX26B gene (550 bp downstream of DDX26B exon 8) and placed the 5’ MLL region 3,951 bp upstream of the
CT45A2 gene. As a result of the insertion, the CT45A1 gene was also deleted.
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the 3’ region of DDX26B (exons 9-16) and the CT45A1
gene, was deleted.
The loss of 11q23 material led to an interstitial dele-
tion on the der(11) chromosome. A more centromeric
g e n el o c a t e da t1 1 q 2 3 . 3 ,FXYD2,w a sf o u n dt ob el o c a -
lized upstream of MLL exons 10-37. However, the intact
FXYD2 gene is oriented telomere to centromere, thus
giving rise to a transcript into the opposing direction
with regard to the orientation of the remaining 3’-MLL
gene. Nevertheless, the 3’-MLL gene could possibly be
transcribed from the recently identified gene internal
promoter upstream of MLL exon 12 [18], resulting in
5’-truncated MLL protein fragment of about 230 kDa.
However, transcripts starting directly at MLL intron11/
exon12 borderline can hardly be distinguished from
endogenous MLL transcripts deriving from the intact
chromosome 11. Therefore, we investigated this not
further.
Characterization of MLL-CT45A2 Fusion Transcripts
RT-PCR with an sense primer located on MLL exon 8
and an antisense primer located on CT45A2 exon 2
resulted in two PCR amplimers of 407 bp (weak) and
481 bp (strong), respectively (Figure 3A). Additional
RT-PCR analysis with antisense primers located on
CT45A2 exon 3 and a sense primer located on MLL
exon 8 gave additional support to these results (data not
shown). Sequencing of the 481 bp amplification product
followed by a BLAST search confirmed that MLL exon
9 was fused in-frame with nucleotide 240 of the
CT45A2 transcript (GenBank accession no. NM_152582;
see Figure 3B). This fusion transcript contains 6 bp
from the 5-UTR of CT45A2 exon 2 fortuitously coding
for two additional amino acids (Figure 3, marked in
red). The fainter 407 bp amplification product was also
sequenced, and an out-of-frame splicing of MLL exon 8
to CT45A2 exon 2 was detected that leads to a prema-
ture stop codon 14 nucleotides downstream of the splice
junction (Figure 3C). The in-frame fusion is predicted to
give rise to a chimeric protein where the N-terminus of
MLL is fused to the entire open reading frame
of CT45A2. The putative MLL-CT45A2 fusion protein
of 1,514 amino acids contains 1,325 amino acids from
the N-terminal portion of MLL and 189 amino acids
deriving from the CT45A2 protein.
Search for DNA Recombination-Associated Motifs
We searched all the breakpoint regions (2000 bp each
side) for interspersed repeats and low complexity DNA
sequences. All breakpoint regions were found to be rich
in long repetitive sequences (Figure 4): MLL intron 9
(four SINE/Alu sequences), DDX26B intron 8 (three
SINE/Alu sequences, two LINE/L1 sequences, two
LINE/L2 sequences, and one SINE/MIR sequence), the
5’CT45A2 breakpoint region (three SINE/Alu sequences,
one LINE/L1 sequence, four LTR/ERVL sequences, two
LTR/MaLR sequences, and one low complexity repeat),
and the 3’FXYD2 breakpoint region (two SINE/Alu
sequences, two SINE/MIR sequences, and one low com-
plexity repeat). Homology search showed that two of
the Xq26.3 SINE/Alu sequences located 3’ of the
DDX26B breakpoint (2189-2492 bp) and 5’ of the
CT45A2 breakpoint (155-391 bp) where highly homolo-
gous (77%) (Figure 4). Moreover, we searched the vici-
nity of the breakpoint junctions (25 bp each side) for
short repetitive sequences and found an inverted repeat
(TTCACTT-AAGTGAAA) flanking the 5’CT45A2
breakpoint junction (-9 to -3 bp and +1 to +7 bp). How-
ever, all analyzed chromosomal breakpoints were always
located outside of these repetitive DNA sequences, indi-
cating that they are possibly not involved in the recom-
bination event.
Discussion
We have identified a novel fusion partner of MLL,t h e
CT45A2 gene, which is a member of the Cancer/Testis
(CT) gene family cluster localized at Xq26.3. In our
pediatric patient with de novo biphenotypic acute leuke-
mia, the MLL-CT45A2 fusion resulted from a cryptic
insertion of 11q23 material into Xq26.3. The insertion of
the 5’MLL region upstream of the CT45A2 gene leads to
MLL-CT45A2 fusion transcripts. In our case, a weaker
transcript exhibited MLL exons 1-8 fused to CT45A2
exon 2 and consecutive exons. This transcript is out-of-
frame and produces only a truncated version of the MLL
protein. The stronger PCR product, however, represented
an in-frame fusion transcript containing MLL exons 1-9
fused to the intact CT45A2 transcript, a process known
as spliced MLL fusion since the chimeric MLL-CT45A2
is only generated at the RNA level [8]. Interestingly, the
chimeric mRNA contains 6 bp from the 5-UTR of
CT45A2 exon 2 resulting in two additional amino acids.
To our knowledge, this is the first description of a spliced
MLL fusion resulting from an insertion event. Indeed,
spliced MLL fusions were previously described in leuke-
mia patients with the translocations t(1;11) (MLL-EPS15),
t(4;11) (MLL-AFF1), t(9;11) (MLL-MLLT3), t(11;15)
(MLL-MPFYVE), t(11;19) (MLL-MLLT1) and t(11;22)
(MLL-SEPT5) [6,8,19], as well as in a single leukemia
patient with an intrachromosomal 11q23 deletion (MLL-
DCPS) [11]. Spliced MLL fusions can occur either by
transcriptional read-through followed by a subsequent
splice event or by trans-splicing [11]. Regardless of the
underlying mechanism, the chimeric MLL-CT45A2
fusion is only produced at the RNA level. A reciprocal
CT45A2-MLL transcript does not exist because the
FXYD2 gene, transcribing in the opposite direction, is
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Page 5 of 9Figure 3 Detection and analysis of the MLL-CT45A2 fusion transcript. (A) RT-PCR analysis with a MLL sense primer located in MLL exon 8
and one CT45A2 sense primer located in CT45A2 exon 2 (lane 1). Lane 2 - 100 bp molecular marker. (B) Partial sequence of the junction of the
MLL-CT45A2 e9e2 chimeric mRNA, showing the nucleotide sequence of the fusion transcript containing 6 bp (in red) from the 5’ UTR of CT45A2
exon 2 coding for two additional amino acids. The arrow shows the in-frame fusion between MLL exon 9 and CT45A2 exon 2. (C) Partial
sequence of the junction of the MLL-CT45A2 e8e2 chimeric mRNA, showing the nucleotide sequence of the fusion transcript. The arrow shows
the out-of-frame fusion between MLL exon 8 and CT45A2 exon 2 that leads to a premature stop codon 14 nucleotides downstream of fusion
breakpoint.
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However, we cannot exclude that the recently described
gene-internal promoter upstream of MLL exon 12 is able
to produce a 5’-truncated MLL protein of about 230 kDa
[18].
Another consequence of this spliced fusion is that the
expression of the CT45A2 gene, usually restricted to tes-
ticular tissue [20], is activated. CT genes encode a het-
erogeneous group of immunogenic proteins
(CT antigens) that were initially identified as immuno-
genic tumor antigens and whose expression is almost
restricted to the normal testis and a percentage of var-
ious tumor types, including melanoma and carcinomas
of the bladder, lung and liver [20-24]. The combination
of restricted normal tissue expression, spontaneous
immunogenicity and frequent tumor expression has
made these antigens attractive targets for cancer vac-
cines [21,24]. The CT45 gene family comprises six
members (CT45A1 to CT45A6) located in Xq26.3 that
are near-identical gene copies, suggesting the occurrence
of recent gene duplications, but whose function remains
to be elucidated [20]. The phenotypic consequences of
CT45A2 expression in the leukemia cells of this patient
are currently unknown. However, as CT45A2 exhibits
the typical CT antigen immunogenic profile, it would be
worthy to further investigate the possible humoral and
cell-mediated immune responses to this protein.
Detailed analysis of the genomic breakpoint junctions
in our patient revealed the presence of filler-DNA
nucleotides and an inverted repeat flanking the break-
point junction 5’ of CT45A2. The repair of chromoso-
mal double-strand breaks (DSBs) occurs by two types of
DNA repair pathways: homologous recombination and
non-homologous end-joining (NEHJ) [25,26]. The pre-
sence of filler-DNA at breakpoints junctions are typical
hallmarks of NHEJ [27], and inverted repeats may
facilitate the formation of secondary structure inter-
mediates between DNA ends at translocation break-
points [13]. Moreover, all breakpoint regions were found
to be rich in repetitive sequences, particularly LINE/L1
elements and SINE/Alu repeats. Although repetitive
sequences may occur near or spanning breakpoint junc-
tions by chance, it is plausible that introns or genomic
regions with a high density of repetitive sequences, such
as MLL i n t r o n9 ,a r em o r ev u l n e r a b l et ob r e a k i n ga n d
non-homologous pairing that can lead to gene fusions.
However, since the chromosomal breakpoints in our
patient were always located outside of these repetitive
DNA sequences, it is unlikely that they could be directly
involved in the recombination events.
The insertion of 11q23 in Xq26.3 was associated with
the deletion of the 3’ region of DDX26B (encompassing
exons 9-16), leading to a premature termination of
ddx26b open-reading frame (ORF). The DDX26B
[DEAD/H (Asp-Glu-Ala-Asp/His) box polypeptide 26B]
protein is a helicase that belongs to the DEAD/DEAH
box family of proteins that are considered to be RNA
helicases, which have been described to be necessary
for, or involved in, many different processes of RNA
metabolism [28]. In eukaryotic cells, in particular, these
range from transcription to degradation of RNA, and
include pre-mRNA splicing, mRNA export, ribosome
biogenesis, translation, initiation, and gene expression in
organelles [28]. Since our patient is a male, the only
functional copy of DDX26B is disrupted as a result of
the insertion, leading to the absence of the DDX26B
protein in the cell or, in alternative, the presence of a
truncated protein. Since the particular function of
DDX26B in myeloid cells is not known, the phenotypic
impact of this abnormality cannot be predicted. The
insertion was also associated with loss of the only copy
of the CT45A1 gene present in the cell. However, since
Figure 4 Schematic representation of the 11q23.3 and Xq26.3 breakpoint regions. The localization of the long repetitive sequences
including the two highly homologous Alu sequences located in the vicinity of the Xq26.3 breakpoint is depicted. L1 (LINE/L1), L2 (LINE/L2), Alu
(SINE/Alu), LCR (Low Complexity Repeat), MIR (SINE/MIR), ERVL (LTR/ERVL), MaLR (LTR/MaLR). None of the breakpoints were located inside these
repetitive elements.
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cellular impact of its loss is not expected to be relevant.
Similarly, the phenotypic impact, if any, of the insertion
i nX q 2 6 . 3o f1 6a d d i t i o n a l1 1 q 2 3g e n e s( FXYD6,
TMPRSS13, IL10RA, APOO2962.2, TMPRSS4, SCN4B,
SCN2B, AMICA1, MPZL3, MPZL2, CD3E, CD3D,
CD3G, UBE4A, ATP5L,a n dAP001267.2) can also not
be predicted.
Conclusion
We have identified CT45A2 as a novel spliced MLL
fusion partner in a pediatric patient with de novo biphe-
notypic acute leukemia, as a result of a cryptic insertion
of 11q23 in Xq26.3. Since CT45A2 is the first Cancer/
Testis antigen family gene found fused with MLL in
acute leukemia, future studies addressing its biologic
relevance for leukemogenesis are warranted.
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